We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Predicting Preterm Babies

By HospiMedica staff writers
Posted on 13 Mar 2005
Using a proprietary technology platform, researchers have profiled the amniotic fluid called metabolome in order to identify which women who have experienced preterm labor are also at risk of delivering a preterm baby.

The researchers studied the amniotic fluid of three groups of patients: those with preterm labor who delivered at term, those with intra-amniotic inflammation who had both preterm labor and delivery, and those with no sign of inflammation who still had preterm labor and delivery.

"We discovered that by using metabolic profiling, 96% of the time we could identify the patients as belonging to the appropriate clinical group,” noted Roberto Romero, M.D., primary study author and chief of the Perinatology Research Branch of the U.S. More...
National Institute of Child Health and Human Development (NICHD; Bethesda, MD, USA). "A second study, in a different set of patients with a larger sample size, has already confirmed the effectiveness of our method. Until now, we have never had a way to predict the course of preterm labor with such accuracy.”

The study results were presented at the annual Scientific Meeting of the Society for Maternal-Fetal Medicine on February 10, 2005, in Reno (NV,USA). Metabolon, Inc. (Research Triangle Park, NC, USA) is leading the discovery of biomarkers through the use of metabolomics, a powerful and new scientific approach for the discovery and development of drugs and the early diagnosis of disease.

"Our successful profiling of the amniotic fluid metabolome and the identification of key biomarkers will aid researchers in the development of tools to determine preterm delivery risk,” said John Ryals, president and CEO of Metabolon.





Related Links:
NICHD
Metabolon

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Syringe Pump
SP50 Series
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.